Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

Floquet control uses time-periodic drives to engineer quantum systems, creating dynamic changes in material properties ...

Could the first confirmed signal from an extraterrestrial source be less a hello than a goodbye? Astrophysicist David Kipping argues as much, and his “Eschatian Hypothesis” reimagines the way ...

BHPian BlackBeard recently shared this with other enthusiasts:Hello folks. Since many enthusiasts here are keen on knowing ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Addressing the core issues of latency and integration in developing audio amplifiers for today’s smart cockpits.

Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

The evacuation of bulk electrical power over long distances can be done mainly by high voltage alternating current (HVAC) ...

Everyday life is saturated with location-dependent devices. They are multiplying faster than ever and their requirements have ...

Precision BioSciences, Inc. , a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today ...